ALLO Stock Analysis: Allogene Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 721m USD | 12M Return: 85.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.6M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. Its allogeneic platform relies on cells from healthy donors rather than from each patient, with the aim of producing off-the-shelf treatments that can be manufactured at scale, unlike conventional autologous CAR T therapies.
The pipeline is built around engineered allogeneic CAR T cell candidates developed using protein engineering, gene editing, gene insertion, and proprietary T cell manufacturing. Lead programs include cema-cel, targeting CD19 for large B-cell lymphoma (LBCL); ALLO-316, targeting CD70 for renal cell carcinoma (RCC); and ALLO-329, a dual CD19/CD70 candidate for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
As a clinical-stage biotechnology company, Allogene has no approved products on the market and its valuation is largely tied to clinical trial readouts and regulatory milestones. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
- Cema-cel ALPHA3 Phase 2 data readout in LBCL
- Cash runway extension drives potential dilution risk
- Autologous CAR-T competition from Gilead and BMS pressures market share
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 4.62 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -109.2m > Net Income -173.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.3m) vs 12m ago 11.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.00%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: -140.8 > 6 (EBIT TTM -172.5m / Interest Expense TTM 1.23m) |
| A: 0.62 (Total Current Assets 273.3m - Total Current Liabilities 28.3m) / Total Assets 396.0m |
| B: -5.19 (Retained Earnings -2.05b / Total Assets 396.0m) |
| C: -0.38 (EBIT TTM -172.5m / Avg Total Assets 452.0m) |
| D: 2.38 (Book Value of Equity 278.9m / Total Liabilities 117.1m) |
| Altman-Z'' = -12.91 = D |
As of July 08, 2026, the stock is trading at USD 2.15 with a total of 14,391,692 shares traded. Over the past week, the price has changed by -3.15%, over one month by +16.22%, over three months by -17.94% and over the past year by +85.34%.
Current recommended Stop Loss: 1.90 (which is 11.6% or 1.8 ATR below the current price).
Allogene Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy ALLO.
- StrongBuy: 8
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8.5 | 294.9% |
P/S = 7784.3633
P/B = 2.5743
Revenue TTM = 0.0 USD
EBIT TTM = -172.5m USD
EBITDA TTM = -160.4m USD
Long Term Debt = 72.6m USD (estimated: total debt 81.1m - short term 8.42m)
Short Term Debt = 8.42m USD (from shortTermDebt, last quarter)
Debt = 153.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 72.6m
Net Debt = -113.2m USD (calculated: Debt 153.7m - CCE 266.9m)
Enterprise Value = 608.2m USD (721.4m + Debt 153.7m - CCE 266.9m)
Interest Coverage Ratio = -140.8 (Ebit TTM -172.5m / Interest Expense TTM 1.23m)
EV/FCF = -4.74x (Enterprise Value 608.2m / FCF TTM -128.2m)
FCF Yield = -21.08% (FCF TTM -128.2m / Enterprise Value 608.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 77.2m) / Revenue TTM)
Tobins Q-Ratio = 1.54 (Enterprise Value 608.2m / Total Assets 396.0m)
Interest Expense / Debt = 0.80% (Interest Expense 1.23m / Debt 153.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -136.3m (EBIT -172.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.22 (Total Current Assets 273.3m / Total Current Liabilities 33.3m)
Debt / Equity = 0.55 (Debt 153.7m / totalStockholderEquity, last quarter 278.9m)
Debt / EBITDA = 0.71 (negative EBITDA) (Net Debt -113.2m / EBITDA -160.4m)
Debt / FCF = 0.88 (negative FCF - burning cash) (Net Debt -113.2m / FCF TTM -128.2m)
Total Stockholder Equity = 307.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.45% (Net Income -173.8m / Total Assets 396.0m)
RoE = -56.45% (Net Income TTM -173.8m / Total Stockholder Equity 307.8m)
RoCE = -45.35% (EBIT -172.5m / Capital Employed (Equity 307.8m + L.T.Debt 72.6m))
RoIC = -36.25% (negative operating profit) (NOPAT -136.3m / Invested Capital 376.0m)
WACC = 9.20% (E(721.4m)/V(875.1m) * Re(11.03%) + D(153.7m)/V(875.1m) * Rd(0.80%) * (1-Tc(0.21)))
Discount Rate = 11.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 17.14%
[DCF] Fair Price = unknown (Cash Flow -128.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.19 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=+10.30% | Revisions=+40% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.14 | Chg30d=+17.44% | Revisions=+40% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.61 | Chg30d=+9.20% | Revisions=+17% | GrowthEPS=+28.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.68 | Chg30d=+1.84% | Revisions=-29% | GrowthEPS=-12.5% | GrowthRev=+216118.5%
[Analyst] Revisions Ratio: +21% (up=7, down=4)